Trial Profile
A Randomized Open-label Study of the Antiviral Efficacy and Safety of Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV), Each in Combination with Two Nucleosides in Subjects Who Have Experienced Virologic Failure with Prior Protease Inhibitor-Containing HAART Regimen(s)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Atazanavir (Primary) ; Lopinavir/ritonavir
- Indications HIV infections
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 19 Dec 2006 Status change
- 11 Oct 2005 New trial record.